Denali Therapeutics’ Chief Medical Officer Buys 170K Shares, Signals Long‑Term Confidence Amid Rising Rare‑Disease Pipeline
Denali Therapeutics CMO’s long‑term option holdings signal confidence; investors gain insight into future growth and alignment of executive incentives.
3 minutes to read
